6578 Share Price Performance
Recent 6578 News & Updates
No updates
DaBomb Protein Biotech Corp. Key Details
Last Reported Earnings
Mar 31, 2025
Next Reporting Earnings
n/a
- Earnings per share (EPS)
- 0.10
- Gross Margin
- 21.45%
- Net Profit Margin
- 2.26%
- Debt/Equity Ratio
- 14.4%
DaBomb Protein Biotech Corp. Competitors
About 6578
- Founded
- 2001
- Employees
- n/a
- CEO
- WebsiteView website
DaBomb Protein Biotech Corp. engages in the development of antibiotics alternatives in animal health industry. It offers plant protein, including DaBomb-P (Aqua) and DaBomb-P (Livestock); antibiotics alternatives, such as DBT-100 HT and DBT-100 LS; and pet care products comprising Liqui-TIDE bandages. The company was formerly known as DaBomb Protein Corp. and changed its name to DaBomb Protein Biotech Corp. in October 2023. DaBomb Protein Biotech Corp. was founded in 2001 and is based in Tainan, Taiwan.
Taiwanese Market Performance
- 7 Days: 0.5%
- 3 Months: 16.4%
- 1 Year: 5.0%
- Year to Date: 3.0%
In the last week, the market has stayed flat, however the Energy sector stood out, gaining 8.6%. As for the longer term, the market has risen 5.0% in the past 12 months. As for the next few years, earnings are expected to grow by 13% per annum. Market details ›
This week, we’re diving deeper into the world of agentic AI. We’re zeroing in on the core technologies that make these intelligent agents actually reliably work. We explore what all this could mean for software, start-ups, and most importantly, the opportunities and risks each industry faces by adopting Agentic AI.
Continue reading